Literature DB >> 19543298

The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells.

Alice Cristina Rodrigues1, Rui Curi, Fabiana Dalla Vecchia Genvigir, Mario Hiroyuki Hirata, Rosario Dominguez Crespo Hirata.   

Abstract

AIM: Statin disposition and response are greatly determined by the activities of drug metabolizing enzymes and efflux/ uptake transporters. There is little information on the regulation of these proteins in human cells after statin therapy. In this study, the effects of atorvastatin and simvastatin on mRNA expression of efflux (ABCB1, ABCG2 and ABCC2) and uptake (SLCO1B1, SLCO2B1 and SLC22A1) drug transporters in Caco-2 and HepG2 cells were investigated.
METHODS: Quantitative real-time PCR was used to measure mRNA levels after exposure of HepG2 and Caco-2 cells to statins.
RESULTS: Differences in mRNA basal levels of the transporters were as follows: ABCC2>ABCG2>ABCB1>SLCO1B1>>>SLC22A1>SLC O2B1 for HepG2 cells, and SLCO2B1>>ABCC2>ABCB1>ABCG2>>>SLC22A1 for Caco-2 cells. While for HepG2 cells, ABCC2, ABCG2 and SLCO2B1 mRNA levels were significantly up-regulated at 1, 10 and 20 micromol/L after 12 or 24 h treatment, in Caco-2 cells, only the efflux transporter ABCB1 was significantly down-regulated by two-fold following a 12 h treatment with atorvastatin. Interestingly, whereas treatment with simvastatin had no effect on mRNA levels of the transporters in HepG2 cells, in Caco-2 cells the statin significantly down-regulated ABCB1, ABCC2, SLC22A1, and SLCO2B1 mRNA levels after 12 or 24 h treatment.
CONCLUSION: These findings reveal that statins exhibits differential effects on mRNA expression of drug transporters, and this effect depends on the cell type. Furthermore, alterations in the expression levels of drug transporters in the liver and/or intestine may contribute to the variability in oral disposition of statins.Acta Pharmacologica Sinica (2009) 30: 956-964; doi: 10.1038/aps.2009.85; published online 22 June 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543298      PMCID: PMC4006650          DOI: 10.1038/aps.2009.85

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  49 in total

1.  Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa.

Authors:  A R Hilgers; R A Conradi; P S Burton
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

Review 2.  Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Authors:  F Thiebaut; T Tsuruo; H Hamada; M M Gottesman; I Pastan; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

4.  Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.

Authors:  A Mohammadi; J Macri; R Newton; T Romain; D Dulay; K Adeli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-05       Impact factor: 8.311

5.  Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.

Authors:  Catherine A M Stedman; Christopher Liddle; Sally A Coulter; Junichiro Sonoda; Jacqueline G A Alvarez; David D Moore; Ronald M Evans; Michael Downes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

6.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

Authors:  I Nicoletti; G Migliorati; M C Pagliacci; F Grignani; C Riccardi
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

7.  Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.

Authors:  D D Cilla; L R Whitfield; D M Gibson; A J Sedman; E L Posvar
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

8.  Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

Authors:  Daisuke Kobayashi; Takashi Nozawa; Kozue Imai; Jun-ichi Nezu; Akira Tsuji; Ikumi Tamai
Journal:  J Pharmacol Exp Ther       Date:  2003-04-30       Impact factor: 4.030

Review 9.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.

Authors:  L Z Benet; C L Cummins; C Y Wu
Journal:  Curr Drug Metab       Date:  2003-10       Impact factor: 3.731

Review 10.  The complexities of hepatic drug transport: current knowledge and emerging concepts.

Authors:  Priyamvada Chandra; Kim L R Brouwer
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.580

View more
  14 in total

1.  Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models.

Authors:  Wei Zhou; Liu-qing Di; Juan Wang; Jin-jun Shan; Shi-jia Liu; Wen-zheng Ju; Bao-chang Cai
Journal:  Acta Pharmacol Sin       Date:  2012-07-09       Impact factor: 6.150

2.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

3.  Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.

Authors:  Mingqing Chen; Claudia Neul; Elke Schaeffeler; Franziska Frisch; Stefan Winter; Matthias Schwab; Hermann Koepsell; Shuiying Hu; Stefan Laufer; Sharyn D Baker; Alex Sparreboom; Anne T Nies
Journal:  Clin Pharmacol Ther       Date:  2019-09-03       Impact factor: 6.875

4.  Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.

Authors:  Zidong Donna Fu; Julia Yue Cui; Curtis D Klaassen
Journal:  J Lipid Res       Date:  2014-10-02       Impact factor: 5.922

5.  Intestinal absorption characteristics of imperialine: in vitro and in situ assessments.

Authors:  Qing Lin; Li-qin Ling; Ling Guo; Tao Gong; Xun Sun; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

6.  Enteric microbiome metabolites correlate with response to simvastatin treatment.

Authors:  Rima Kaddurah-Daouk; Rebecca A Baillie; Hongjie Zhu; Zhao-Bang Zeng; Michelle M Wiest; Uyen Thao Nguyen; Katie Wojnoonski; Steven M Watkins; Miles Trupp; Ronald M Krauss
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

7.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

Review 8.  The genetics of hyperuricaemia and gout.

Authors:  Anthony M Reginato; David B Mount; Irene Yang; Hyon K Choi
Journal:  Nat Rev Rheumatol       Date:  2012-09-04       Impact factor: 20.543

Review 9.  ABC Transport Proteins in Cardiovascular Disease-A Brief Summary.

Authors:  Toni Schumacher; Ralf A Benndorf
Journal:  Molecules       Date:  2017-04-06       Impact factor: 4.411

10.  Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.

Authors:  Ondrej Martinec; Carin Biel; Inge A M de Graaf; Martin Huliciak; Koert P de Jong; Frantisek Staud; Filip Cecka; Peter Olinga; Ivan Vokral; Lukas Cerveny
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.